Amedeo Smart

Free Medical Literature Service


 

Amedeo

Multiple Sclerosis

  Free Subscription

05.02.2024

1 AJNR Am J Neuroradiol
1 Arch Phys Med Rehabil
1 BMC Neurol
1 Brain
5 J Neurol
2 J Neurol Sci
3 Mult Scler
1 Neurology



    AJNR Am J Neuroradiol

  1. ZHANG HQ, Lee JC, Wang L, Cao P, et al
    Dynamic Changes in Long-Standing Multiple Sclerosis Revealed by Longitudinal Structural Network Analysis Using Diffusion Tensor Imaging.
    AJNR Am J Neuroradiol. 2024 Feb 1. doi: 10.3174/ajnr.A8115.
    >> Share


    Arch Phys Med Rehabil

  2. SILVEIRA SL, Motl RW, Salter A, Marquez DX, et al
    Social cognitive theory variables as correlates of physical activity behavior among Hispanics with multiple sclerosis.
    Arch Phys Med Rehabil. 2024 Jan 26:S0003-9993(24)00053.
    >> Share


    BMC Neurol

  3. LE HH, Ken-Opurum J, LaPrade A, Maculaitis MC, et al
    Exploring humanistic burden of fatigue in adults with multiple sclerosis: an analysis of US National Health and Wellness Survey data.
    BMC Neurol. 2024;24:51.
    >> Share


    Brain

  4. HERRANZ E, Treaba CA, Barletta VT, Mehndiratta A, et al
    Characterization of cortico-meningeal translocator protein expression in multiple sclerosis.
    Brain. 2024 Jan 30:awae030. doi: 10.1093.
    >> Share


    J Neurol

  5. BAJRAMI A, Tamanti A, Peloso A, Ziccardi S, et al
    Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis.
    J Neurol. 2024 Jan 30. doi: 10.1007/s00415-023-12179.
    >> Share

  6. BOUMAN PM, van Dam MA, Jonkman LE, Steenwijk MD, et al
    Isolated cognitive impairment in people with multiple sclerosis: frequency, MRI patterns and its development over time.
    J Neurol. 2024 Jan 30. doi: 10.1007/s00415-024-12185.
    >> Share

  7. NAUTA IM, Kessels RPC, Bertens D, Stam CJ, et al
    Neurophysiological brain function predicts response to cognitive rehabilitation and mindfulness in multiple sclerosis: a randomized trial.
    J Neurol. 2024 Jan 26. doi: 10.1007/s00415-024-12183.
    >> Share

  8. BISECCO A, Matrone F, Capobianco M, De Luca G, et al
    COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.
    J Neurol. 2023 Nov 20. doi: 10.1007/s00415-023-12084.
    >> Share

  9. RIVEL M, Achiron A, Stern Y, Zeilig G, et al
    Emotional burden among MS patients: associations between specific chronic pain diagnoses and psychological features.
    J Neurol. 2023 Oct 24. doi: 10.1007/s00415-023-12048.
    >> Share


    J Neurol Sci

  10. HJAERESEN S, Benedikz E, Sejbaek T, Axelsson M, et al
    High temperature requirement A1 and macrophage migration inhibitory factor in the cerebrospinal fluid; a potential marker of conversion from relapsing-remitting to secondary progressive multiple sclerosis.
    J Neurol Sci. 2024;457:122888.
    >> Share

  11. ZANETTA C, Faustino P, Guerrieri S, Nozzolillo A, et al
    Fast but not furious: Rapid ocrelizumab infusion as a strategy to optimize multiple sclerosis patients' management.
    J Neurol Sci. 2024;457:122897.
    >> Share


    Mult Scler

  12. NAKAMURA K, Thoomukuntla B, Bena J, Cohen JA, et al
    Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis.
    Mult Scler. 2024 Jan 29:13524585231224702. doi: 10.1177/13524585231224702.
    >> Share

  13. SWITAL M, Drouin J, Miranda S, Bakchine S, et al
    Use of multiple sclerosis disease-modifying therapies during pregnancy in France: Nationwide study between 2010 and 2021.
    Mult Scler. 2024 Jan 27:13524585231223395. doi: 10.1177/13524585231223395.
    >> Share

  14. MISCIOSCIA A, Treaba CA, Barletta VT, Herranz E, et al
    White matter paramagnetic rim and non-rim lesions share a periventricular gradient in multiple sclerosis: A 7-T imaging study.
    Mult Scler. 2024 Jan 27:13524585231224681. doi: 10.1177/13524585231224681.
    >> Share


    Neurology

  15. BRIDGE F, Brotherton J, Stankovich J, Sanfilippo PG, et al
    Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies.
    Neurology. 2024;102:e208059.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016